H. Roché

发表

Improved survival at 2 and 5 years in the LMCE1 unselected group of 72 children with stage IV neuroblastoma older than 1 year of age at diagnosis: is cure possible in a small subgroup?

J. Zucker, E. Bouffet, T. Philip, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

RESILIENCE: Phase III Randomized, Double‐Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2‐Negative Breast Cancer

J. Bergh, C. Hudis, W. Gradishar, 2017, Clinical breast cancer.

Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.

M. Espié, J. Baselga, P. Hoff, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.

J. Bonneterre, A. Monnier, I. van Praagh, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation.

J. Wanders, E. Raymond, J. Beijnen, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Alternative methodological approach to randomized trial for surgical procedures routinely used.

F. Dalenc, T. Filleron, E. Jouve, 2018, Contemporary clinical trials.

Population P harmacokinetics o f t he N ovel A nticancer Agent E 7070 D uring F our P hase I S tudies: M odel B uilding and V alidation

J. Wanders, C. Punt, E. Raymond, 2002 .

Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam

J. Wanders, C. Punt, E. Raymond, 2005, Investigational New Drugs.

Epirubicin–vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial

M. Namer, J. Bonneterre, A. Monnier, 2007, British Journal of Cancer.

Taxanes in adjuvant breast cancer setting: which standard in Europe?

M. Campone, P. Fumoleau, P. Kerbrat, 2005, Critical reviews in oncology/hematology.

Patients' regrets after participating in a randomized controlled trials depended on their involvement in the decision making.

P. Viens, J. Mancini, C. Tarpin, 2012, Journal of clinical epidemiology.

Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer.

J. Jassem, X. Pivot, H. Chung, 2009, European journal of cancer.

Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.

T. Delozier, J. Bonneterre, B. Asselain, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Impact of Taxotere on Adjuvant Breast Cancer

P. Fumoleau, H. Roché, 2005 .

Q‐TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer

G. Hortobagyi, D. Revicki, P. Conte, 2012, Cancer.

Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results.

M. Namer, J. Bonneterre, A. Monnier, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Assessment of care by breast cancer patients participating or not participating in a randomized controlled trial: a report with the Patients' Committee for Clinical Trials of the Ligue Nationale Contre le Cancer.

A. Monnier, C. Tarpin, F. Dalenc, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

M4 protocol for cerebellar medulloblastoma: supratentorial radiotherapy may not be avoided.

D. Frappaz, E. Bouffet, C. Raybaud, 1992, International journal of radiation oncology, biology, physics.

Factors predicting the sentinel node metastases in T1 breast cancer tumor: an analysis of 1416 cases.

D. Querleu, G. Ferron, E. Mery, 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

The importance of jointly analyzing treatment administration and toxicity associated with targeted therapies: a case study of regorafenib in soft tissue sarcoma patients

T. Brodowicz, N. Penel, J. Boher, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Dexamethasone as a probe for docetaxel clearance

F. Dalenc, T. Cresteil, C. Chevreau, 2004, Cancer Chemotherapy and Pharmacology.

Dexamethasone as a probe for vinorelbine clearance.

F. Dalenc, T. Cresteil, E. Chatelut, 2005, British journal of clinical pharmacology.

Participants’ uptake of clinical trial results: a randomised experiment

P. Viens, J. Mancini, C. Tarpin, 2010, British Journal of Cancer.

Population pharmacokinetics of carboplatin in children

A. Boddy, D. Newell, P. Canal, 1996, Clinical pharmacology and therapeutics.

High-dose sequential chemotherapy with recombinant granulocyte colony-stimulating factor and repeated stem-cell support for inflammatory breast cancer patients: does impact on quality of life jeopardize feasibility and acceptability of treatment?

T. Delozier, P. Viens, J. Moatti, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective construction and validation of a prognostic score to identify patients who benefit from third-line chemotherapy for metastatic breast cancer in terms of overall survival: the METAL3 Study.

F. Dalenc, F. Bonnetain, T. Filleron, 2015, Contemporary clinical trials.

Decision-making and breast cancer clinical trials: how experience challenges attitudes.

A. Monnier, J. Mancini, C. Tarpin, 2007, Contemporary clinical trials.

Cost-effectiveness of adjuvant docetaxel for node-positive breast cancer patients: results of the PACS 01 economic study.

P. Viens, P. Fumoleau, P. Marino, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group.

R. Paridaens, J. Bonneterre, B. Thürlimann, 1997, European journal of cancer.

Results of a phase II trial with cystemustine in advanced malignant melanoma. A trial of the EORTC Clinical Screening Group.

P. Fumoleau, P. Fargeot, P. Kerbrat, 1996, European journal of cancer.

Should this patient participate n a randomized clinical trial ?

X. Morandi, J. Gauvrit, P. Courtheoux, 2010 .

Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study.

H. Wildiers, J. Jassem, L. Dirix, 2015, Breast.

Ixabepilone alone or with cetuximab as first-line treatment for advanced/metastatic triple-negative breast cancer.

R. Vyzula, M. Campone, J. Jassem, 2015, Clinical breast cancer.

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.

R. Paridaens, J. Wanders, M. Campone, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER 2-Positive Breast Cancer

R. Greil, E. Winer, Minetta C. Liu, 2009 .

Treatment of metastatic breast cancer: second line and beyond.

L. Vahdat, H. Roché, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.

W. Eiermann, H. Rugo, Y. Im, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial

W. Eiermann, H. Rugo, L. Fehrenbacher, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial)

T. Delozier, V. Bardou, P. Viens, 1999, British Journal of Cancer.

MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study

F. Bertucci, D. Birnbaum, P. Finetti, 2016, Oncotarget.

Phase II Study of Oral Idarubicin in Elderly Patients with Advanced Breast Cancer

M. Namer, M. Marty, A. Monnier, 1990, American journal of clinical oncology.

Joint pain with aromatase inhibitors: abnormal frequency of Sjögren's syndrome.

M. Laroche, H. Roché, B. de Lafontan, 2007, The Journal of rheumatology.

Risk adapted chemotherapy for localised Ewing's sarcoma of bone: the French EW93 study.

B. Bui, O. Oberlin, J. Michon, 2012, European journal of cancer.

Preirradiation chemotherapy including "eight drugs in 1 day" regimen and high-dose methotrexate in childhood medulloblastoma: results of the M7 French Cooperative Study.

C. Mottolese, J. Stéphan, J. Zucker, 1995, Journal of neurosurgery.

Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer

T. Delozier, D. Spaeth, P. Biron, 2008, Bone Marrow Transplantation.

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.

H. Gómez, Bing-he Xu, M. Campone, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Five-Year Analysis of the FNCLCC-PACS04 Trial: FEC100 vs ED75 for the Adjuvant Treatment of Node Positive Breast Cancer.

L. Mauriac, J. Canon, G. Romieu, 2009 .

Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG).

J. Wanders, M. Ravic, J. Schellens, 2003, European journal of cancer.

Combined results of 4 phase I and pharmacokinetic (PK) studies of E7070, a novel chloroindolyl-sulphonamide inhibiting the activation of cdk2 and cyclin E

J. Wanders, E. Raymond, A. Calvert, 2000 .

A recombinant cell bioassay for measurement of overall estrogenic activity of serum: preliminary results in women with breast cancer

J. Nicolas, F. Dalenc, J. Faye, 2004, Clinical chemistry and laboratory medicine.

Docetaxel in sequential therapy for node-positive, early-stage breast cancer

H. Roché, 2006 .

The effects of food on the pharmacokinetic profile of oral vinorelbine

P. Fumoleau, G. Robinet, R. Bugat, 2002, Cancer Chemotherapy and Pharmacology.

Pharmacokinetic (PK) Interactions between Lapatinib (L) and Vinorelbine (VNR) in a Phase I Study in Locally Advanced or Metastatic Breast Cancer (LAMBC) Patients(Pts) Overexpressing HER2. GEP-01 – A Study of the FNCLCC-Group of Early Phase Trials.

J. Bonneterre, P. Fumoleau, V. Diéras, 2009 .

Dermatological adverse events with taxane chemotherapy

M. Lacouture, F. Dalenc, L. Gladieff, 2016, European Journal of Dermatology.

Isabelle Gasnereau, M. Lamuraglia, H. Roché, 2018, BMC Cancer.

Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial.

A. Ravaud, B. Bui, J. Mihura, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer

J. Baselga, N. Harbeck, N. Radosevic-Robin, 2015, Breast Cancer Research and Treatment.

Combination Therapy With Ixabepilone Plus Capecitabine Is Effective in ER/PR/HER2-Negative Breast Cancer Resistant to Anthracyclines and Taxanes

M. Piontek, H. Roché, M. Verrill, 2008 .

Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials

E. Perez, G. Hortobagyi, J. Sparano, 2012, Supportive Care in Cancer.

Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies

E. Perez, G. Hortobagyi, Bing-he Xu, 2011, Breast Cancer Research and Treatment.

Ixabepilone plus capecitabine improves overall survival in symptomatic patients with metastatic breast cancer previously treated with anthracycline and taxane in 2 large phase III studies.

E. Perez, G. Hortobagyi, Bing-he Xu, 2009 .

Phase III trial of ixabepilone plus capecitabine compared to capecitabine alone in patients with metastatic breast cancer (MBC) previously treated or resistant to an anthracycline and resistant to taxanes

H. Gómez, J. Jassem, H. Chung, 2007 .

LBA8A PHASE III RANDOMIZED, DOUBLE-BLIND, TRIAL COMPARING SORAFENIB PLUS CAPECITABINE VERSUS PLACEBO PLUS CAPECITABINE IN THE TREATMENT OF LOCALLY ADVANCED OR METASTATIC HER2-NEGATIVE BREAST CANCER (RESILIENCE)

J. Bergh, C. Hudis, W. Gradishar, 2014 .

High-dose chemotherapy for breast cancer: the French PEGASE experience.

B. Asselain, P. Biron, P. Viens, 2003, Cancer control : journal of the Moffitt Cancer Center.

Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer

H. Rugo, J. Hopkins, Miguel Martín, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase II trial of dasatinib in triple-negative breast cancer: results of study CA180059.

N. Ibrahim, J. Sparano, R. Finn, 2009 .

Identification of a basal-like subtype and comparative effect of epirubicin-based chemotherapy and sequential epirubicin followed by docetaxel chemotherapy in the PACS 01 breast cancer trial: 33 markers studied on tissue-microarrays (TMA).

F. Penault-Llorca, E. Charafe-Jauffret, S. Marque, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical pharmacodynamic factors in docetaxel toxicity

F. Goldwasser, E. Chatelut, J. Treluyer, 2007, British Journal of Cancer.

A French prospective pilot study for identifying dihydropyrimidine dehydrogenase (DPD) deficiency in breast cancer patients (pts) receiving capecitabine (cap)

F. Pinguet, J. Bonneterre, G. Romieu, 2013 .

Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02 and 07 trials.

M. Namer, J. Bonneterre, M. Campone, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Dexamethasone as a probe for CYP3A4 metabolism: evidence of gender effect

A. Sparreboom, E. Chatelut, J. Delord, 2007, Cancer Chemotherapy and Pharmacology.

Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial.

S. Schraub, M. Namer, J. Bonneterre, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors of contralateral breast cancer (CBC) in 3,653 early breast cancer (EBC) patients (pts): 9-year follow-up results of French Adjuvant Study Group (FASG) trials.

M. Namer, J. Bonneterre, A. Monnier, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Trial of Cystemustine, a New Nitrosourea, as Treatment of High-grade Brain Tumors in Adults

J. Madelmont, P. Fumoleau, P. Fargeot, 2000, Journal of Neuro-Oncology.

Inflammatory breast cancer outcome with epirubicin‐based induction and maintenance chemotherapy

P. Fumoleau, P. Fargeot, P. Kerbrat, 2006, Cancer.

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

W. Eiermann, H. Rugo, I. C. Tudor, 2018, The New England journal of medicine.

Benefit of the Sequential Administration of Docetaxel after Standard FEC Regimen for Node-Positive Breast Cancer: Long-Term Follow-Up Results of the FNCLCC-PACS 01 Trial.

T. Delozier, M. Campone, T. Petit, 2009 .

Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.

S. Schraub, M. Namer, J. Bonneterre, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

10-year follow-up update of French adjuvant study group 05 trial: FEC 100 regimen remains superior to FEC 50 in adjuvant chemotherapy of poor prognosis, node-positive, early breast cancer patients

M. Namer, J. Bonneterre, P. Fumoleau, 2003 .

Analysis of germline BRCA1/2 mutated (gBRCAmut) hormone receptor-positive (HR+) and triple negative breast cancer (TNBC) treated with talazoparib (TALA).

W. Eiermann, H. Rugo, I. C. Tudor, 2018 .

Prediction of recurrence with the Oncotype DX recurrence score in node-positive, HR-positive, breast cancer patients treated with adjuvant chemotherapy: Results from PACS01 trial.

S. Shak, F. Baehner, F. Penault-Llorca, 2014 .

Evaluation of the Theoretical Teaching of Postgraduate Radiation Oncology Medical Residents in France: a Cross-Sectional Study

S. Culine, J. Bibault, J. Salleron, 2018, Journal of Cancer Education.

Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer

J. Baselga, M. Campone, J. Boni, 2005 .

Tamoxifen plus bromocriptine versus tamoxifen plus placebo in advanced breast cancer: results of a double blind multicentre clinical trial.

J. Bonneterre, L. Mauriac, P. Fargeot, 1988, European journal of cancer & clinical oncology.

Late epidermal growth factor receptor inhibitor‐related papulopustular rash: a distinct clinical entity

H. Roché, J. Delord, V. Sibaud, 2016, Clinical and experimental dermatology.

P1.01A phase 3 study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with advanced breast cancer (EMBRACA)

W. Eiermann, H. Rugo, M. Martín, 2015 .

[Intensive chemotherapy and autograft of hematopoietic stem cells in the treatment of metastatic cancer: results of the national protocol Pegase 04].

B. Asselain, C. Gisselbrecht, J. Lotz, 1999, Hematology and Cell Therapy.

Pharmacokinetic evaluation of the vinorelbine–lapatinib combination in the treatment of breast cancer patients

J. Bonneterre, S. Urien, V. Diéras, 2011, Cancer Chemotherapy and Pharmacology.

A Phase I Dose-Escalating and Pharmacokinetic Study of Docetaxel and Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer

F. Pinguet, L. Nguyen, F. Dalenc, 2008, Oncology.

Model‐Based Quantification of Impact of Genetic Polymorphisms and Co‐Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast Cancer

J. Robert, N. Dohollou, F. Dalenc, 2020, Clinical pharmacology and therapeutics.

An attempt to treat pediatric intracranial αFP and βHCG secreting germ cell tumors with chemotherapy alone. SFOP experience with 18 cases

C. Patte, E. Sariban, E. Bouffet, 1998, Journal of Neuro-Oncology.

A phase I study of ixabepilone in combination with epirubicin in patients with metastatic breast cancer.

L. Gianni, F. Dalenc, M. Zambetti, 2012, Clinical breast cancer.

T‐DM1 extravasation: first description

H. Roché, J. Delord, V. Sibaud, 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

[Angiosarcoma of the breast].

B. Malavaud, H. Roché, P. Martel, 1989, Journal de gynecologie, obstetrique et biologie de la reproduction.

A Clinical Screening Cooperative Group phase II evaluation of lobaplatin (ASTA D-19466) in advanced head and neck cancer

J. Armand, M. David, H. Roché, 2004, Investigational New Drugs.

Curability of third ventricular region tumours

M. Gigaud, H. Roché, E. Suc, 1989, Acta Neurochirurgica.

An attempt to treat pediatric intracranial alphaFP and betaHCG secreting germ cell tumors with chemotherapy alone. SFOP experience with 18 cases. Société Française d'Oncologie Pédiatrique.

C. Patte, E. Sariban, E. Bouffet, 1998, Journal of neuro-oncology.

Coexpression of androgen receptor and FOXA1 in nonmetastatic triple-negative breast cancer: ancillary study from PACS08 trial.

J. Lemonnier, M. Lacroix-Triki, M. Campone, 2015, Future oncology.

Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer

R. Greil, E. Winer, Minetta C. Liu, 2009, Clinical Cancer Research.

PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy

G. Romieu, P. Lamy, F. Dalenc, 2019, Breast Cancer Research and Treatment.

Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study.

T. Delozier, M. Campone, T. Petit, 2012, The Lancet. Oncology.

A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.

A. Howell, S. Lundgren, W. Eiermann, 1996, European journal of cancer.

Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer.

A. Tres, J. Mayordomo, N. Ibrahim, 2011, The oncologist.

Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study

N. Ibrahim, J. Sparano, R. Finn, 2011, Clinical Cancer Research.

Phase II, 3-arm study of CCI-779 in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer: preliminary results.

J. Baselga, H. Burstein, P. Fumoleau, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer.

P. Fumoleau, P. Fargeot, P. Kerbrat, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A multicentric prospective study of intensive induction chemotherapy (API-AI) in localized osteosarcoma patients: Results of a phase II trial coordinated by the French Sarcoma Group (FSG) and the FNCLCC BECT.

J. Blay, B. Bui, A. Le Cesne, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials.

D. Berry, S. Rodenhuis, J. Bergh, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inflammatory Breast Cancer: Pilot Study of Intensive Induction Chemotherapy (FEC‐HD) Results in a High Histologic Response Rate

P. Hurteloup, P. Chollet, H. Roché, 1993 .

UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup.

J. Lemonnier, M. Campone, J. Canon, 2019, European journal of cancer.

Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial.

J. Machiels, F. Penault-Llorca, B. Asselain, 2012, The oncologist.

A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA).

W. Eiermann, H. Rugo, Y. Im, 2015 .

Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer

J. Machiels, M. Lacroix-Triki, M. Campone, 2014, Breast Cancer Research.

3LBA SOLTI-0701: A double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib (SOR) compared to placebo (PL) when administered in combination with capecitabine (CAP) in patients (pts) with locally advanced (adv) or metastatic (met) breast cancer (BC)

J. Baselga, A. Lluch, A. Giglio, 2009 .

High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocol.

T. Delozier, B. Asselain, C. Gisselbrecht, 2005, European journal of cancer.

Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients.

C. Sotiriou, F. Bertucci, D. Birnbaum, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.

J. Mackey, W. Eiermann, T. Pintér, 2011, The Lancet. Oncology.

Sequential cisplatin/VM-26 and vincristine/cyclophosphamide/doxorubicin in metastatic neuroblastoma: an effective alternating non-cross-resistant regimen?

D. Frappaz, J. Zucker, T. Philip, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Improving survival in recurrent medulloblastoma: earlier detection, better treatment or still an impasse?

J. Stéphan, E. Sariban, E. Bouffet, 1998, British Journal of Cancer.

New advances in DPYD genotype and risk of severe toxicity under capecitabine

F. Pinguet, C. Béroud, A. V. van Kuilenburg, 2017, PloS one.

A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC.

P. Fumoleau, V. Diéras, P. Kerbrat, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.

M. van Glabbeke, M. Glabbeke, P. Fumoleau, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tipifarnib Plus Tamoxifen in Tamoxifen-Resistant Metastatic Breast Cancer: A Negative Phase II and Screening of Potential Therapeutic Markers by Proteomic Analysis

B. Monsarrat, G. Favre, F. Dalenc, 2010, Clinical Cancer Research.

Genetics and epidemiology of Wilms' tumor: the French Wilms' tumor study.

C. Bonaïti‐pellié, J. Hochez, A. Chompret, 1992, Medical and pediatric oncology.

High rate of extra-haematological toxicity compromises dose-dense sequential adjuvant chemotherapy for breast cancer

B. Asselain, L. Mauriac, P. Fumoleau, 2011, British Journal of Cancer.

Optimal duration of adjuvant chemotherapy for high-risk node-negative (N-) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106).

J. Lemonnier, B. Asselain, M. Campone, 2017, European journal of cancer.

Abstract GS6-07: EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation

W. Eiermann, I. C. Tudor, Y. Im, 2018 .

FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial.

F. Penault-Llorca, R. Boidot, P. Fumoleau, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine

J. Armand, P. Canal, F. Lokiec, 2004, Cancer Chemotherapy and Pharmacology.

HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome.

F. Dalenc, C. Chevreau, J. Delord, 2011, The oncologist.

CO21. HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome

F. Dalenc, C. Chevreau, J. Delord, 2011 .

Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial.

J. Bonneterre, A. Monnier, P. Fumoleau, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy.

J. Sparano, L. Mauriac, D. Lebwohl, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS04 trial

F. Penault-Llorca, J. Lemonnier, J. Canon, 2013, Breast Cancer Research and Treatment.

Pathological Response and Circulating Tumor Cell Count Identifies Treated HER2+ Inflammatory Breast Cancer Patients with Excellent Prognosis: BEVERLY-2 Survival Data

J. Bonneterre, M. Campone, T. Petit, 2014, Clinical Cancer Research.

EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT)

E. Winer, V. Diéras, C. Oliva, 2007 .

Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series

M. Lacouture, K. Busam, S. Modi, 2014, Breast Cancer Research and Treatment.

Docetaxel combined with targeted therapies in metastatic breast cancer.

J. Cortés, H. Roché, 2012, Cancer treatment reviews.

Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer.

F. Penault-Llorca, F. André, M. Lacroix-Triki, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.

S Michiels, B Asselain, J Bogaerts, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial.

J. Machiels, T. Delozier, F. Penault-Llorca, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors of young women (≤ 35 years) with node positive breast cancer: possible influence on post-therapeutic follow-up.

J. Canon, P. Fumoleau, Anne-Laure Martin, 2013, Bulletin du cancer.

Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated Metastatic Breast Cancer

F. Bertucci, X. Pivot, P. Viens, 2017, Cancer research and treatment : official journal of Korean Cancer Association.

[The reproduction in France of Rosen's protocol for osteosarcomas].

J. Gentet, M. Brunat-mentigny, H. Roché, 1988, Bulletin du cancer.

Cost-Effectiveness Analysis of Trastuzumab (Herceptin) in HER2-Overexpressed Metastatic Breast Cancer

Jean-Paul Moatti, M. Marty, P. Viens, 2009, American journal of clinical oncology.

Impact of uncertainty on cost-effectiveness analysis of medical strategies: The case of high-dose chemotherapy for breast cancer patients

J. Moatti, P. Marino, C. Siani, 2005, International Journal of Technology Assessment in Health Care.

Metastatic medulloblastoma: the experience of the French Cooperative M7 Group.

E. Bouffet, C. Lasset, F. Doz, 1994, European journal of cancer.

Cystemustine in recurrent high grade glioma

J. Lemaire, J. Chazal, X. Durando, 2006, Journal of Neuro-Oncology.

Carboplatin and VP 16 in medulloblastoma: a phase II Study of the French Society of Pediatric Oncology (SFOP).

E. Sariban, E. Bouffet, F. Doz, 1994, Medical and pediatric oncology.

[Anaplastic temporal ganglioglioma with spinal metastasis].

E. Uro-Coste, J. Sabatier, H. Roché, 2001, Annales de pathologie.

Pharmacokinetics and toxicity of two modalities of etoposide infusion in metastatic non-small-cell lung carcinoma

G. Houin, P. Canal, C. Chevreau, 2008, Cancer Chemotherapy and Pharmacology.

Abstract OT1-03-16: EMBRACA: A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) versus physician's choice in BRCA mutation subjects with locally advanced and/or metastatic breast cancer

W. Eiermann, Y. Im, M. Martín, 2016 .

Compliance with ASCO 2006 recommendations for the use of "white blood cell growth factors" in advanced lung cancer (LC) or breast cancer (BC) or non-Hodgkin lymphoma (NHL): An interim analysis of French National Observational Study—The ZOHé study.

C. Haioun, P. Solal-Céligny, H. Roché, 2014 .

Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer

S. Kaye, D. Bisset, P. Vasey, 2002, British Journal of Cancer.

Tetracosactrin vs. methylprednisolone in the prevention of emesis in patients receiving FEC regimen for breast cancer.

J. Bonneterre, P. Fargeot, P. Kerbrat, 1991, European journal of cancer.

Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes

G. Hortobagyi, H. Gómez, Bing-he Xu, 2010, Breast Cancer Research and Treatment.

Phase II study of cystemustine in metastatic colorectal carcinoma. A trial of the EORTC Clinical Screening Group.

P. Fumoleau, P. Kerbrat, P. Chollet, 1993, European journal of cancer.

Ifosfamide is an active drug in Wilms' tumor: a phase II study conducted by the French Society of Pediatric Oncology.

O. Taboureau, F. Demeocq, M. Tournade, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neurotoxicity as a Prognostic Factor in Patients with Metastatic Breast Cancer Treated with Ixabepilone as a First-Line Therapy

M. Mouret-Reynier, C. Abrial, F. Kwiatkowski, 2014, Oncology.

Weekly paclitaxel: an effective and well-tolerated treatment in patients with advanced breast cancer.

H. Lück, H. Roché, 2002, Critical reviews in oncology/hematology.

BCIRG 007: Serum HER2 levels in women with metastatic HER2-amplified breast cancer

M. Buyse, J. Mackey, J. Canon, 2007 .

SOLTI-0701: A Multinational Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo When Administered in Combination with Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer (BC).

J. Baselga, E. Ciruelos, P. Gómez, 2009 .

Ixabepilone plus capecitabine vs capecitabine in patients with triple negative tumors: a pooled analysis of patients from two large phase III clinical studies.

E. Perez, H. Rugo, H. Chung, 2009 .

A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer.

P. Fumoleau, V. Diéras, P. Kerbrat, 1996, British Journal of Cancer.

Ixabepilone plus capecitabine improves progression free survival in patients with metastatic breast cancer resistant to taxanes: a pooled analysis from two phase III trials.

J. Sparano, P. Conte, J. Ro, 2009 .

Efficacy and Safety of Ixabepilone and Capecitabine in Patients With Advanced Triple‐negative Breast Cancer: a Pooled Analysis From Two Large Phase III, Randomized Clinical Trials

H. Rugo, H. Chung, L. Vahdat, 2018, Clinical breast cancer.

UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer.

H. Wildiers, J. Lemonnier, M. Lacroix-Triki, 2018, European journal of cancer.

Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure

M. Namer, J. Bonneterre, A. Monnier, 2002, British Journal of Cancer.

Epirubicin‐Docetaxel Combination in First‐Line Chemotherapy for Patients With Metastatic Breast Cancer: Final Results of a Dose‐Finding and Efficacy Study

T. Delozier, P. Viens, P. Fumoleau, 2001, American journal of clinical oncology.

Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience.

M. Namer, J. Bonneterre, L. Mauriac, 1999, European journal of cancer.

Stage IE nonHodgkin's lymphoma of the testis: a need for a brief aggressive chemotherapy.

H. Roché, E. Suc, M. Carton, 1989, The Journal of urology.

Safety analysis from PACS 04-A phase III trial comparing 6 cycles of FEC100 with 6 cycles of ET75 for node-positive early breast cancer patients, followed by sequential trastuzumab in HER2+ patients: Preliminary results.

T. Delozier, B. Asselain, J. Canon, 2006, Journal of Clinical Oncology.

A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial

C. Hudis, W. Gradishar, J. Baselga, 2013, Trials.

Choosing a career in oncology: results of a nationwide cross-sectional study

S. Culine, J. Bibault, J. Salleron, 2018, BMC medical education.

[Choroidal metastasis as a presenting feature of breast carcinoma].

G. Martin-Blondel, L. Astudillo, H. Roché, 2007, La Revue de medecine interne.

Phase II study of pirarubicin (THP) in patients with cervical, endometrial and ovarian cancer: study of the Clinical Screening Group of the European Organization for Research and Treatment of Cancer (EORTC).

J. Armand, P. Fumoleau, P. Kerbrat, 1993, European journal of cancer.

Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.

J. Forbes, M. Buyse, G. Sauter, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC - PACS 01 randomized trial

F. Bertucci, D. Birnbaum, P. Finetti, 2011, Breast Cancer Research.

Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis.

G. Hortobagyi, L. Pusztai, J. Mackey, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of obesity on disease-free and overall survival in node-positive breast cancer patients in a large French population: a pooled analysis of two randomised trials.

P. Fumoleau, Anne-Laure Martin, M. Spielmann, 2014, European journal of cancer.

Population pharmacokinetics and pharmacokinetic‐pharmacodynamic relationships of the novel anticancer agent E7070 in four phase I studies

J. Wanders, E. Raymond, J. Schellens, 2002 .

Clinical activity of ixabepilone, a novel epothilone b analog, across the breast cancer disease continuum

M. Piontek, E. Kubista, X. Pivot, 2008 .

How to report toxicity associated with targeted therapies?

A. Ravaud, B. Escudier, N. Penel, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Failure event types and prognostic factors after node-positive breast cancer in patients treated by adjuvant chemotherapy: impact on follow-up.

P. Fumoleau, Anne-Laure Martin, F. Dalenc, 2012, Bulletin du cancer.

Original Paper EYcacy and Safety of Docetaxel (Taxotere 2 ) in Heavily Pretreated Advanced Breast Cancer Patients: the French Compassionate Use Programme Experience

M. Namer, J. Bonneterre, L. Mauriac, 1999 .

Methodology of phase II clinical trials in metastatic elderly breast cancer: a literature review

F. Dalenc, T. Filleron, J. Boher, 2017, Breast Cancer Research and Treatment.

A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes

J. Bonneterre, M. Campone, G. Milano, 2012, Cancer Chemotherapy and Pharmacology.

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials).

H. Wildiers, J. Bogaerts, J. Yarnold, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Neoadjuvant sequential treatment in women with breast cancer: FEC100 then docetaxel: Results in clinical practice

M. Lacroix-Triki, M. Marty, F. Dalenc, 2004 .

C. Récher, L. Gladieff, Noémie Gadaud, 2015, Dermatology.

Deterioration of quality of life of high-risk breast cancer patients treated with high-dose chemotherapy: the PEGASE 01 Quality of Life Study.

T. Delozier, D. Spaeth, P. Biron, 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Abstract P3-15-04: A French prospective pilot study to identify dihydropyrimidine dehydrogenase (DPD) deficiency in breast cancer patients receiving capecitabine

F. Pinguet, J. Bonneterre, G. Romieu, 2013 .

A phase 1 study of vinflunine in combination with trastuzumab for the treatment for HER2-positive metastatic breast cancer

R. Paridaens, H. Wildiers, O. Rixe, 2012, Cancer Chemotherapy and Pharmacology.

External validation of a published nomogram for prediction of brain metastasis in patients with extra-cerebral metastatic breast cancer and risk regression analysis.

F. Dalenc, T. Filleron, H. Roché, 2017, European journal of cancer.

[Breast ductal carcinoma in situ with microinvasion: pathological review and clinical implications].

T. Filleron, E. Mery, H. Roché, 2014, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

1198 Treatment of localized Ewing's sarcoma in young adults. A study of the French society of pediatric oncology

J. Zucker, N. Dohollou, O. Oberlin, 1995 .

Systemic therapy of inflammatory breast cancer from high‐dose chemotherapy to targeted therapies

F. Bertucci, P. Viens, C. Tarpin, 2010, Cancer.

Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group.

M. Namer, J. Bonneterre, M. Campone, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Arthralgia Associated with Autoimmune Abnormalities under Aromatase Inhibitor Therapy: Outcome after Cessation of Treatment

A. Ruyssen-Witrand, M. Laroche, H. Roché, 2016, The Journal of Rheumatology.

1 Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer

F. Bertucci, D. Birnbaum, P. Finetti, 2017 .

Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer

F. Bertucci, D. Birnbaum, P. Finetti, 2011, Breast Cancer Research and Treatment.

UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer.

J. Lemonnier, J. Pierga, P. Viens, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial

R. Bataille, M. Campone, F. Magrangeas, 2009, Breast Cancer Research and Treatment.

3. A randomized trial of the new specific aromatase inhibitor ‘Arimidex’ (anastrozole) versus megestrol acetate (MA) in the treatment of postmenopausal women with advanced breast cancer (ABC)

A. Howell, S. Lundgren, W. Eiermann, 1995 .

Economic issues involved in integrating genomic testing into clinical care: the case of genomic testing to guide decision-making about chemotherapy for breast cancer patients

F. Bertucci, P. Viens, P. Marino, 2011, Breast Cancer Research and Treatment.

Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

Bingshu E. Chen, R. Gray, P. Lønning, 2023, The Lancet.

High-Dose Chemotherapy for Patients With High-Risk Breast Cancer: A Clinical and Economic Assessment Using a Quality-Adjusted Survival Analysis

J. Moatti, P. Marino, H. Roché, 2008, American journal of clinical oncology.

Individualized Prediction of Menses Recovery After Chemotherapy for Early‐stage Breast Cancer: A Nomogram Developed From UNICANCER PACS04 and PACS05 Trials

J. Lemonnier, M. Campone, B. Pistilli, 2019, Clinical breast cancer.

Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS Study

J. Robert, F. Dalenc, W. Jacot, 2019, Clinical pharmacology and therapeutics.

Results of a phase II trial with second-line cystemustine at 60 mg/m2 in advanced soft tissue sarcoma: a trial of the EORTC Early Clinical Studies Group.

P. Fumoleau, P. Kerbrat, P. Chollet, 1998, European journal of cancer.

Does time interval between surgery and adjuvant chemotherapy initiation modify treatment efficacy in operable, breast cancer patients? French Adjuvant Study Group (FASG) results

M. Namer, J. Bonneterre, A. Monnier, 2005 .

SOLTI NeoPARP: A phase II, randomized study of two schedules of iniparib plus paclitaxel and paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer (TNBC).

J. Baselga, F. Penault-Llorca, A. Lluch, 2012 .

[Anticancer drug adherence].

G. Laurent, F. Despas, H. Roché, 2013, Bulletin du Cancer.

Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix.

M. van Glabbeke, P. Fumoleau, V. Diéras, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Larotaxel (L) in combination with trastuzumab in patients with HER2 + metastatic breast cancer (MBC): Interim analysis of an open phase II label study

H. Bonnefoi, G. Romieu, P. Viens, 2008 .

Vinflunine in combination with trastuzumab for treatment of HER2-positive metastatic breast cancer

R. Paridaens, H. Wildiers, F. Dalenc, 2007 .

Phase II Trials of Tetrahydropyranyl‐Adriamycin (Pirarubicin) on Renal and Colon Carcinoma, Melanoma, and Soft Tissue Sarcoma

P. Hérait, J. Armand, P. Fumoleau, 1993, American journal of clinical oncology.

Cost-Effectiveness Analysis of Trastuzumab (Herceptin) in HER2-Overexpressed Metastatic Breast Cancer

M. Marty, P. Viens, J. Moatti, 2009, American journal of clinical oncology.

Prediction of carboplatin clearance from standard morphological and biological patient characteristics.

G. Houin, P. Canal, C. Chevreau, 1995, Journal of the National Cancer Institute.

The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial)

S. Shak, F. Baehner, F. Penault-Llorca, 2018, BMC Cancer.

333PCIRCULATING TUMOR CELL COUNT AT BASELINE IS AN INDEPENDENT PROGNOSTIC FACTOR FROM PATHOLOGICAL COMPLETE RESPONSE AMONG PATIENTS TREATED FOR PRIMARY INFLAMMATORY HER2-POSITIVE BREAST CANCER: SURVIVAL RESULTS OF THE BEVERLY-2 STUDY.

J. Bonneterre, M. Campone, T. Petit, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Choosing a career in oncology: results of a nationwide cross-sectional study

S. Culine, J. Bibault, J. Salleron, 2018, BMC Medical Education.

[Primary dural lymphoma: a report of two cases with review of the literature].

J. Richaud, H. Roché, J. Delord, 2003, Revue neurologique.

Benefit of neoadjuvant capecitabine + epirubicin + cyclophosphamide (CEX) versus 5-FU + epirubicin + cyclophosphamide (FEC) for operable breast cancer (BC) followed by adjuvant docetaxel (T)

F. Penault-Llorca, G. Milano, P. Fumoleau, 2008 .